China
-
Esteve CDMO invests US$80M to expand manufacturing operations in China
Once expanded, the facility could have a total reactor volume exceeding 400 m³, increasing the company’s capacity to develop and manufacture active pharmaceutical ingredients (APIs).
-
HighTide Therapeutics presents HTD1801 results for polycystic kidney disease at ASN Kidney Week 2026
The findings extend previous research into HTD1801’s potential to address kidney impairment associated with metabolic abnormalities.
-
Gilead strikes US$1.28B PepStar deal in China for oral inflammation drug
Gilead is exploring HCXT-2001 as a potential oral treatment that could complement its existing inflammation portfolio, which includes programmes targeting IBD, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune conditions.
-
Everest Medicines appoints former Moderna scientists to strengthen global mRNA research
Both executives previously held leadership positions at Moderna, where they worked on messenger RNA (mRNA) cancer vaccines, including mRNA-4157/V940.
-
Everest Medicines receives priority review for local VELSIPITY manufacturing in China
The NMPA approved VELSIPITY in February 2026 for adults with moderately to severely active ulcerative colitis (UC) who had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.
-
Novo Nordisk licenses Hengrui’s HRS-1596 in China deal to expand oral obesity pipeline
The Danish pharmaceutical company will receive exclusive rights to develop, manufacture and commercialise HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan.
-
MSD licenses KRAS G12D drug from China’s SciBrunch in US$2.13B oncology deal
The deal comes as pharmaceutical companies increase investment in therapies that target RAS, a family of proteins involved in regulating cell growth and division.
-
Amberstone Biosciences partners with Henlius on tumour-activated T-cell engagers
T cell engagers are designed to bring a patient’s T cells into contact with cancer cells, enabling the immune cells to attack the tumour.
-
Boehringer Ingelheim sells China biologics CDMO unit to Shanghai RAAS
Shanghai-based Raas disclosed the proposed acquisition in a financial filing, stating that it plans to acquire a 100% stake in Boehringer Ingelheim Biopharmaceuticals in China.
-
Novartis licenses preclinical radioligand asset from China’s BoomRay in US$900M global deal
The agreement brings together BoomRay’s expertise in radioligand therapy development and Novartis’ global capabilities in radiopharmaceutical research and commercialisation.